Business Wire Industry News

Monday, November 28, 2022

Alpha Cognition Announces Third Quarter 2022 Results and Provides Corporate Update

VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reported financial results and provided a corporate update for the third quarter ended September 30, 2022. "The Company continues to prepare its NDA filing for ALPHA-1062 for mild to moderate

Monday, November 28, 2022

FSD Pharma Announces Changes to the Board of Directors

TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, is pleased to announce the appointments of Dr. Lakshmi P. Kotra and Mr. Joseph L. Romano to its Board of Directors, effective November 25, 2022. Effective at the same time was the resignation of Fernando Cugliari from the Board of

Monday, November 28, 2022

Cimeio Therapeutics Announces Issuance of Key Patent Covering Cell Therapy Platform

BASEL, Switzerland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies, today announced the U.S. Patent Office has issued a key patent covering the company’s Shielded-Cell & Immunotherapy Pairs (SCIP) platform. U.S. Patent No. 11,499,168 covers a method for in vivo selective depletion of edited primary hematopoietic cells or non-edited primary hematopoietic cells. This method was first discovered and developed in th

Monday, November 28, 2022

Enveric Biosciences Announces Confidential Submission of Registration Statement for the Spin-off of its Cannabinoid Business to Shareholders

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, today announced the confidential submission of a Form S-1 draft registration statement with the U.S. Securities and Exchange Commission (‘SEC’) for the spin-off its cannabinoid clinical development pipeline to a wholly-owned subsidiary, Akos B

Friday, November 25, 2022

IMV Receives Nasdaq Notification Regarding Market Value of Listed Securities

DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #DeliveryPlatform--IMV Inc. (“IMV” or the “Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced that, on November 22, 2022, the Company received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company's Market Value of Listed Sec

Tuesday, November 22, 2022

Wellbeing Digital Announces the Appointment of Mohammad Sharifi to Board of Directors

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $KONEF #psychedelics--Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces the appointment of Mohammad Sharifi to the Wellbeing Board of Directors (“the Board”), effective November 22, 2022. Mr. Mohammad

Tuesday, November 22, 2022

Zymeworks Announces Participation in Upcoming Investor Conference

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference: 5th Annual Evercore ISI HealthCONx Conference. Zymeworks’ management will participate in one-on-one meetings on November 29th – December 1st and a fireside chat on November 29th at 4:45 pm Eastern Standard Time (EST). All presentations

Tuesday, November 22, 2022

ImmunoPrecise Antibodies Ltd. Announces Voluntary Delisting from TSX Venture Exchange

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA) announces that it has applied and has received approval for a voluntary delisting of its common shares from the TSX Venture Exchange (“TSXV”). Accordingly, it is anticipated that, effective as at the close of trading on Friday, November 25, 2022, IPA’s common shares will no longer be listed and posted for trading on the TSXV. The delisting from the TSXV will not af

Tuesday, November 22, 2022

VBI Vaccines Presents Additional Phase 1/2a Data from VBI-1901 in Recurrent GBM at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that additional biomarker data from the Phase 1/2a study of VBI-1901, the Company’s cancer vaccine immunotherapeutic candidate in recurrent glioblastoma (GBM), were presented at the 27th Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO), on Friday, November 18, 2022. In t